Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice

Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice

Abstract Gypenoside XIII is isolated from Gynostemma pentaphyllum (Thunb.) Makino. In mice, G. pentaphyllum extract and gypenoside LXXV have been shown to improve non‐alcoholic steatohepatitis (NASH). This study investigated whether gypenoside XIII can regulate lipid accumulation in fatty liver cell...

Full description

Bibliographic Details
Main Authors:	Shu‐Chen Cheng, Chian‐Jiun Liou, Ya‐Xuan Wu, Kuo‐Wei Yeh, Li‐Chen Chen, Wen‐Chung Huang
Format:	Article
Language:	English
Published:	Wiley 2024-03-01
Series:	Kaohsiung Journal of Medical Sciences
Subjects:	gypenoside XIII inflammation lipogenesis lipolysis non‐alcoholic steatohepatitis
Online Access:	https://doi.org/10.1002/kjm2.12795

Similar Items

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
by: Jin Ha Lee, et al.
Published: (2020-10-01)

Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation
by: Hongshan Li, et al.
Published: (2022-08-01)

Gypenoside L and Gypenoside LI Inhibit Proliferation in Renal Cell Carcinoma via Regulation of the MAPK and Arachidonic Acid Metabolism Pathways
by: Hui Liu, et al.
Published: (2022-03-01)

Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism
by: Tingting Zhou, et al.
Published: (2023-04-01)

The potential molecular mechanism underlying gypenoside amelioration of atherosclerosis in ApoE−/− mice: A multi-omics investigation
by: Xing Ju, et al.
Published: (2024-04-01)

Targeting MRG15 for the treatment of nonalcoholic steatohepatitis
by: Yao Zhang, et al.
Published: (2022-12-01)

Gender and age effects on the expression of genes related to lipid metabolism in broiler's liver
by: Angélica de Souza Khatlab, et al.
Published: (2018-03-01)

Gypenosides ameliorate ductular reaction and liver fibrosis via inhibition of hedgehog signaling
by: Yonghong Hu, et al.
Published: (2022-11-01)

Gypenoside inhibits gastric cancer proliferation by suppressing glycolysis via the Hippo pathway
by: Li Pan, et al.
Published: (2024-08-01)

Phloretin ameliorates hepatic steatosis through regulation of lipogenesis and Sirt1/AMPK signaling in obese mice
by: Chian-Jiun Liou, et al.
Published: (2020-09-01)

Effect of Gypenosides on the composition of gut microbiota and metabolic activity in the treatment of CCl4-induced liver injury in rats
by: Pengyao Tian, et al.
Published: (2022-10-01)

Enhanced Production of Gypenoside LXXV Using a Novel Ginsenoside-Transforming β-Glucosidase from Ginseng-Cultivating Soil Bacteria and Its Anti-Cancer Property
by: Chang-Hao Cui, et al.
Published: (2017-05-01)

Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes
by: Hongxu Du, et al.
Published: (2019-05-01)

Gypenosides Prevent and Dissolve Cholesterol Gallstones by Modulating the Homeostasis of Cholesterol and Bile Acids
by: Qian Zhuang, et al.
Published: (2022-04-01)

Hybrid sequencing of the Gynostemma pentaphyllum transcriptome provides new insights into gypenoside biosynthesis
by: Tongtong Liang, et al.
Published: (2019-08-01)

Gypenosides attenuate lipopolysaccharide-induced neuroinflammation and anxiety-like behaviors in rats
by: Bombi Lee, et al.
Published: (2018-09-01)

Gypenoside alleviates injury of rat adrenal pheochromocytoma cell line PC12 induced by lipopolysaccharide
by: JIANG Xiu-fang, GENG Ya-nan, YANG Sheng-hong, WEI Ping, ZHAO Ming, ZHU Ling-ling
Published: (2022-06-01)

Label-free proteomic analysis reveals the hepatoprotective mechanism of gypenosides in liver injury rats
by: Yu Chen, et al.
Published: (2024-06-01)

Gypenosides Attenuate Pulmonary Fibrosis by Inhibiting the AKT/mTOR/c-Myc Pathway
by: Suqing Liu, et al.
Published: (2022-01-01)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
by: Jia Xu, et al.
Published: (2022-05-01)

Sesamin ameliorates nonalcoholic steatohepatitis through inhibiting hepatocyte pyroptosis in vivo and in vitro
by: Teng Zhang, et al.
Published: (2024-02-01)

Effects of light quality on growth, total gypenosides accumulation and photosynthesis in <em>Gynostemma pentaphyllum</em>
by: Xiaolie Peng, et al.
Published: (2017-07-01)

Caspase-11–Mediated Hepatocytic Pyroptosis Promotes the Progression of Nonalcoholic SteatohepatitisSummary
by: Yingwei Zhu, et al.
Published: (2021-01-01)

In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis
by: Inmaculada García-Ruiz, et al.
Published: (2015-02-01)

Succinate Enhances Lipolysis and Decreases Adipocytes Size in Both Subcutaneous and Visceral Adipose Tissue from High-Fat-Diet-Fed Obese Mice
by: Tengteng Ji, et al.
Published: (2023-11-01)

Effect of ractopamine on lipid metabolism in vivo - a systematic review
by: Matheus Soares da Silva Ferreira, et al.
Published: (2013-02-01)

Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models
by: Fabio Penna, et al.
Published: (2013-11-01)

Gypenoside XVII protects against myocardial ischemia and reperfusion injury by inhibiting ER stress–induced mitochondrial injury
by: Yingli Yu, et al.
Published: (2021-11-01)

Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats
by: Wenhua Zhu, et al.
Published: (2017-09-01)

Gypenosides Synergistically Reduce the Extracellular Matrix of Hepatic Stellate Cells and Ameliorate Hepatic Fibrosis in Mice
by: Han Li, et al.
Published: (2023-07-01)

Adipose KLF15 Controls Lipid Handling to Adapt to Nutrient Availability
by: Keiichiro Matoba, et al.
Published: (2017-12-01)

Platelet-rich plasma combined with gypenosides for the treatment of psoriasis-like inflammation in mice
by: LI Dandan, et al.
Published: (2024-12-01)

Gypenoside LVI attenuates foam cell formation by promoting cholesterol export and inhibiting inflammation response
by: Chun-Yan Shen, et al.
Published: (2018-11-01)

Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE<sup>−/−</sup> Mice
by: Ming Gao, et al.
Published: (2022-08-01)

Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides
by: Yang G, et al.
Published: (2019-04-01)

Triglyceride peroxidation progression in lipid droplets of hepatocytes in nonalcoholic steatohepatitis
by: Kota Saito, et al.
Published: (2024-02-01)

Gypenosides Inhibit Inflammatory Response and Apoptosis of Endothelial and Epithelial Cells in LPS-Induced ALI: A Study Based on Bioinformatic Analysis and in vivo/vitro Experiments
by: Tu Q, et al.
Published: (2021-01-01)

Gypenoside XVII Reduces Synaptic Glutamate Release and Protects against Excitotoxic Injury in Rats
by: Cheng-Wei Lu, et al.
Published: (2024-05-01)

IMAGING DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS
by: Anca Smaranda Farmazon, et al.
Published: (2018-09-01)

Angiogenesis in alcoholic steatohepatitis, nonalcoholic steatohepatitis and hepatitis C virus infection (immunohistochemical study)
by: Gavrilyuk O.M.
Published: (2013-12-01)